Ⅳ期维吾尔族非小细胞肺癌组织EML4-ALK表达与临床病理特征的关系
发布时间：2018-07-31 08:14
【摘要】：目的肺癌是目前发病率较高的肿瘤,是癌症相关死亡重要的原因之一。NCCN指南已将克唑替尼(Crizotinib)作为EML4-ALK融合基因患者的标准一线治疗。本研究探讨维吾尔族Ⅳ期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的EML4-ALK重排与临床病理特征之间的关系。方法回顾性分析2015-01-01-2016-05-31,在新疆医科大学附属肿瘤医院采用Ventana全自动免疫组化法进行EML4-ALK检测的158例维吾尔族Ⅳ期NSCLC患者的临床资料,分析其临床病理特征与EML4-ALK重排的关系。结果 158例维尔族Ⅳ期NSCLC患者中,检测到EML4-ALK融合基因11例(6.96%)。未检测到EML4-ALK融合基因的患者147例(93.04%)。EML4-ALK突变与吸烟史、患者的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变状况、病理类型有关,P0.05;而与性别、年龄、有无淋巴结转移及分化程度无关,P0.05。无EGFR突变的不吸烟的腺癌患者EML4-ALK融合基因阳性率高。结论EML4-ALK融合基因多表达于腺癌、不吸烟或既往有吸烟史,且同时无EGFR突变的维吾尔族Ⅳ期NSCLC患者。明确Ⅳ期维吾尔族NSCLC患者中EML4-ALK的表达与临床病理学特征之间的联系,便于更好地发现相应的治疗优势人群,进行及时的检测与治疗。
[Abstract]:Objective lung cancer is a high incidence of tumor and is one of the important causes of cancer related death. The.NCCN guide has used Crizotinib as the standard first-line treatment for patients with EML4-ALK fusion gene. This study explores the EML4-ALK rearrangement and presence of non-small cell lung cancer (NSCLC) in Uygur stage IV non small cell lung cancer (NSCLC). The relationship between the pathological features of the bed. Methods a retrospective analysis of the clinical data of 158 Uygur IV NSCLC patients in the Affiliated Tumor Hospital of Xinjiang Medical University, which was detected by Ventana automatic immunohistochemical method by EML4-ALK, was analyzed. The relationship between the clinicopathological features and the EML4-ALK rearrangement was analyzed. Results 158 cases were vill. Of the NSCLC patients with stage IV NSCLC, EML4-ALK fusion gene was detected in 11 cases (6.96%). 147 cases (93.04%) of.EML4-ALK mutation and smoking history were not detected in patients with EML4-ALK fusion gene, the mutation of epidermal growth factor receptor (epidermal growth factor receptor, EGFR), pathological type, P0.05, and lymph node transition with sex and age. It was not related to the degree of migration and differentiation, and the positive rate of EML4-ALK fusion gene was higher in non smoking non smoking adenocarcinoma patients with P0.05. without EGFR mutation. Conclusion EML4-ALK fusion gene is more expressed in adenocarcinoma, no smoking or smoking history, and there is no EGFR mutation in Uygur IV NSCLC patients. The expression and clinical manifestation of EML4-ALK in Uygur NSCLC patients are clearly defined and clinical. The connection between pathological characteristics is conducive to better finding the corresponding treatment of the dominant population, and timely detection and treatment.
【作者单位】： 新疆医科大学附属肿瘤医院肺内科;
【基金】：乌鲁木齐市科技局一般项目(Y161310008) 新疆医科大学创新基金(XJDCX201548)
【分类号】：R734.2
本文编号：2154974
[Abstract]:Objective lung cancer is a high incidence of tumor and is one of the important causes of cancer related death. The.NCCN guide has used Crizotinib as the standard first-line treatment for patients with EML4-ALK fusion gene. This study explores the EML4-ALK rearrangement and presence of non-small cell lung cancer (NSCLC) in Uygur stage IV non small cell lung cancer (NSCLC). The relationship between the pathological features of the bed. Methods a retrospective analysis of the clinical data of 158 Uygur IV NSCLC patients in the Affiliated Tumor Hospital of Xinjiang Medical University, which was detected by Ventana automatic immunohistochemical method by EML4-ALK, was analyzed. The relationship between the clinicopathological features and the EML4-ALK rearrangement was analyzed. Results 158 cases were vill. Of the NSCLC patients with stage IV NSCLC, EML4-ALK fusion gene was detected in 11 cases (6.96%). 147 cases (93.04%) of.EML4-ALK mutation and smoking history were not detected in patients with EML4-ALK fusion gene, the mutation of epidermal growth factor receptor (epidermal growth factor receptor, EGFR), pathological type, P0.05, and lymph node transition with sex and age. It was not related to the degree of migration and differentiation, and the positive rate of EML4-ALK fusion gene was higher in non smoking non smoking adenocarcinoma patients with P0.05. without EGFR mutation. Conclusion EML4-ALK fusion gene is more expressed in adenocarcinoma, no smoking or smoking history, and there is no EGFR mutation in Uygur IV NSCLC patients. The expression and clinical manifestation of EML4-ALK in Uygur NSCLC patients are clearly defined and clinical. The connection between pathological characteristics is conducive to better finding the corresponding treatment of the dominant population, and timely detection and treatment.
【作者单位】： 新疆医科大学附属肿瘤医院肺内科;
【基金】：乌鲁木齐市科技局一般项目(Y161310008) 新疆医科大学创新基金(XJDCX201548)
【分类号】：R734.2
【相似文献】
相关期刊论文 前1条
1 周清;;肺癌中EML4-ALK突变导致对ALK抑制剂耐药的研究[J];循证医学;2010年06期
，本文编号：2154974
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2154974.html
